aaaa Physicians and biopharma should improve accessibility of cancer trials - The Cancer Letter

Physicians and biopharma should improve accessibility of cancer trials

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Oncological clinical trials pave the way for better patient outcomes and accelerate critical cancer treatments. Their legacy structure, however, often stands in their own way.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Michel van Harten, MD
CEO, myTomorrows
Table of Contents

YOU MAY BE INTERESTED IN

Joseph FraiettaPietro GenoveseSwim Across America, the nonprofit funding innovative clinical trials and patient-centered programs for cancer, awarded $450,000 grants to two of its beneficiaries, Alliance for Cancer Gene Therapy and Dana-Farber Cancer Institute, to support the work of novel gene and base editing techniques used in advanced cancer research, including targeted therapies, immunotherapies, and cellular therapies. 
Michel van Harten, MD
CEO, myTomorrows

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login